Philippe Mariette

Philippe Mariette, MD, PhD is Professor of Surgery and Head of the Upper GI Surgical Oncology Unit at the Centre Hospitalier Régional Universitaire (CHRU) de Lille and Université de Lille, and is France's foremost esophageal and gastric cancer surgeon-scientist. He leads one of the highest-volume esophageal cancer surgery programs in France and has been the driving force behind landmark French and European multicenter trials that have defined optimal multimodal treatment strategies for esophageal and gastroesophageal junction cancers. Mariette is best known for leading the PRODIGE 5/ACCORD 17 phase II/III trial comparing FOLFOX plus radiation versus CF plus radiation as neoadjuvant chemoradiotherapy for resectable esophageal cancer, and for the FREGAT (French Eso-Gastric Tumors) multicenter cohort that has generated crucial real-world data on surgical outcomes and survival. He was co-investigator on the ESOPEC phase III trial (Hoeppner et al., NEJM 2024) comparing FLOT perioperative chemotherapy versus CROSS neoadjuvant chemoradiotherapy for resectable esophageal adenocarcinoma—a pivotal head-to-head comparison that demonstrated superior overall survival with FLOT in adenocarcinoma, significantly impacting international treatment strategy. Mariette has authored over 350 peer-reviewed publications and has been a member of ESMO, ESSO, and ISDE guideline development groups. He is internationally recognized for expertise in surgical quality, lymphadenectomy standards, and patient-reported outcomes after esophagectomy, and has been a vocal advocate for multidisciplinary decision-making and clinical trial participation as cornerstones of esophageal cancer care.